Download PDF
Hamostaseologie 1987; 07(05): 109-114
DOI: 10.1055/s-0038-1660539
Originalarbeit
Schattauer GmbH

Physiologie, Pathologie und pharmakologische Effekte des Prostazyklins

Th. Simmet
1   Institut für Pharmakologie und Toxikologie, Ruhr-Universität Bochum, Bochum
,
B. A. Peskar
1   Institut für Pharmakologie und Toxikologie, Ruhr-Universität Bochum, Bochum
› Author Affiliations
Further Information

Publication History

Publication Date:
25 June 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

PGI2 bewirkt über die Erhöhung intrazellulärer cAMP-Spiegel eine Hemmung der Thrombozytenaggregation. Seine zweite Hauptwirkung ist eine Vasodilatation. Die Synthese von PGI2 wird durch eine schädigende Noxe an der Gefäßwand aktiviert, in welcher PGI2 hauptsächlich im Endothel, aber auch in den glatten Muskelzellen synthetisiert wird. Es besteht eine enge Interaktion zwischen korpuskulären Blutbestandteilen, aber auch verschiedenen Plasmafaktoren und der Gefäßwand, die insbesondere bei Verletzungen im Hinblick auf die lokale Hämostase mit Thrombozytenaggregation, Blutgerinnung und lokaler fibrinolytischer Aktivität von Bedeutung zu sein scheint. Mit Ausnahme einiger weniger spezieller Indikationen scheint das natürliche, instabile PGI2 aber bislang nur von limitiertem therapeutischem Nutzen zu sein.

 

  • LITERATUR

  • 1 Aanderud S, Krane H, Nordoy A. Influence of glucose, insulin and sera from diabetic patients on the prostacyclin synthesis in vitro in cultured human endothelial cells. Diabetologica 1985; 28: 641-4.
    CrossrefPubMedGoogle Scholar
  • 2 Acharya S B, MacIntyre D E. Platelet products and vascular PGI2 production. Prostaglandins Leukotrienes Med 1983; 10: 73-81.
    CrossrefPubMedGoogle Scholar
  • 3 Akai T, Naka K, Okuda K, Takemura T, Fujii S. Decreased sensitivity of platelets to prostacyclin in patients with diabetes mellitus. Horm Metabol Res 1983; 15: 523-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Bergström S, Carlson L A, Weeks J R. The prostaglandins: a family of biologically active lipids. Pharmacol Rev 1968; 20: 1-48.
    PubMedGoogle Scholar
  • 5 Boeynaems J M, Galand N. Stimulation of vascular prostacyclin synthesis by extracellular ADP and ATP. Biochem Biophys Res Commun 1983; 112: 290-6.
    CrossrefPubMedGoogle Scholar
  • 6 Boeynaems J M, Galand N, Ketelbant P. Prostacyclin production by the deendothelialized rabbit aorta. J Clin Invest 1985; 76: 7-14.
    CrossrefPubMedGoogle Scholar
  • 7 Bunting S, Moncada S, Vane J R. The prostacyclin-thromboxane A2 balance: pathophysiological and therapeutic implications. Br Med Bull 1983; 39: 271-6.
    CrossrefPubMedGoogle Scholar
  • 8 Bydlowski S P, Yunker R L, Campaigne B N, Kotogal U R, Subbiah M T R. Human breast milk contains a factor which markedly stimulates aortic prostacyclin synthesis. Biochim Biophys Acta 1986; 878: 1-6.
    CrossrefPubMedGoogle Scholar
  • 9 Chesterman C N, Owe-Young R, Macpherson J, Krillis S A. Substrate for endothelial prostacyclin production in the presence of platelets exposed to collagen is derived from platelets rather than the endothelium. Blood 1986; 67: 1744-50.
    PubMedGoogle Scholar
  • 10 Coughlin S R, Moskowitz M A, Zetter B R, Antoniades H N, Levine L. Platelet-dependent stimulation of prostacyclin synthesis by platelet-derived growth factor. Nature 1980; 288: 600-2.
    CrossrefPubMedGoogle Scholar
  • 11 Cramer E B, Pologe L, Pawlowski N A, Cohn Z A, Scott W A. Leukotriene C promotes prostacyclin synthesis by human endothelial cells. Proc Natl Acad Sci USA 1983; 80: 4109-13.
    CrossrefPubMedGoogle Scholar
  • 12 D’Angelo V, Villa S, Mysliwiec M, Donati M B, de Gaetano G. Defective fibrinolytic and prostacyclin-like activity in human atheromatous plaques. Thromb Haemostas 1978; 39: 535-6.
    PubMedGoogle Scholar
  • 13 Dembinska-Kiec A, Zmuda A, Grodzinska L, Bieron K, Basista M, Kedzior A, Kostka-Trabka E, Telesz E, Zelasny T. Increased platelet activity after termination of prostacyclin infusion into man. Prostaglandins 1981; 827-32.
    PubMedGoogle Scholar
  • 14 Dembinska-Kiec A, Kostka-Trabka E, Gryglewski R J. Effect of prostacyclin on fibrinolytic activity in patients with atherosclerosis obliteranç. Thromb Haemostas 1982; 47: 190.
    PubMedGoogle Scholar
  • 15 Ditter H, Heinrich D, Matthias F R, Sellmann-Richter R, Wagner W L, Hehrlein F W. Effects of prostacyclin during cardiopulmonary bypass in men on plasma levels of betathromboglobulin, platelet factor 4, thromboxane B2, 6-keto-prostaglandin Fla and heparin. Thromb Res 1983; 32: 393-408.
    CrossrefPubMedGoogle Scholar
  • 16 Dutta-Roy A K, Ray T K, Sinha A K. Prostacyclin stimulation of the activation of blood coagulation factor X by platelets. Science 1986; 231: 385-8.
    CrossrefPubMedGoogle Scholar
  • 17 Etingin O R, Weksler B B, Hajjar D P. Cholesterol metabolism is altered by hydrolytic metabolites of prostacyclin in arterial smooth muscle cells. I Lipid Res 1986; 27: 530-6.
    PubMedGoogle Scholar
  • 18 Fitscha P, Kaliman I, Sinzinger H. Platelet sensitivity to antiaggregatory prostaglandins (PGEj, D2, I2) in patients with peripheral vascular disease. Am I Haematol 1985; 19: 13-9.
    PubMedGoogle Scholar
  • 19 FitzGerald G A, Oates I A. Selective and nonselective inhibition of thromboxane formation. Clin Pharmacol Ther 1984; 35: 633-40.
    CrossrefPubMedGoogle Scholar
  • 20 FitzGerald G A, Smith B, Pedersen A K, Brash A R. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310: 1065-8.
    CrossrefPubMedGoogle Scholar
  • 21 Gryglewski R J. Deaggregatory action of prostacyclin in vivo and its enhancement by theophylline. Prostaglandins 1978; 15: 637-44.
    CrossrefPubMedGoogle Scholar
  • 22 Guivernau M, Baraona E, Lieber C S. Acute and chronic effects of ethanol and its metabolites on vascular production of prostacyclin in rats. J Pharmacol Exp Ther 1987; 240: 59-64.
    PubMedGoogle Scholar
  • 23 Hall E R, Papp A C, Seifert W E, Wu K K. Stimulation of endothelial cell prostacyclin formation by interleukin-2. Lymphokine Res 1986; 05: 87-96.
    PubMedGoogle Scholar
  • 24 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-8.
    CrossrefPubMedGoogle Scholar
  • 25 Hope W, Martin T J, Chesterman C N, Morgan F J. Human thromboglobulin inhibits PGI2 production and binds to a specific site in bovine aortic endothelial cells. Nature 1979; 282: 210-3.
    CrossrefPubMedGoogle Scholar
  • 26 Jaschonek K, Karsch K R, Weisenberger H, Tidow S, Faul C, Renn W. Platelet prostacyclin binding in coronary artery disease. J Am Coll Cardiol 1986; 08: 259-66.
    CrossrefPubMedGoogle Scholar
  • 27 Johnson E J, Mackie I J, Machin S J, Brozovic B. Preservation of platelet function in cryopreserved platelet concentrated with prostacyclin. Clin Lab Haematol 1984; 06: 141-4.
    PubMedGoogle Scholar
  • 28 Johnson M, Harrison H E, Raftery A T, Elder J B. Prostacyclin and diabetes. In: Clinical Pharmacology of Prostacyclin. Lewis P J, O’Grady J. (eds). New York: Raven Press; 1981: 105-12.
    Google Scholar
  • 29 Johnson R A, Morton D R, Kinner J H, Gorman R R, McGuire J C, Sun F F, Wittacker N, Bunting S, Salmon J, Moncada S, Vane J R. The chemical structure of prostaglandin X (prostacyclin). Prostaglandins 1976; 12: 915-28.
    CrossrefPubMedGoogle Scholar
  • 30 Jolan H, Muszbek L, Stadler I, Fesus L. Inhibition of platelet factor 3 availability by prostacyclin. Prostaglandins 1980; 20: 935-45.
    CrossrefPubMedGoogle Scholar
  • 31 Kiernan F J, Kluger J, Regnier J C, Rutkowski M, Fieldman A. Epoprostenol sodium (prostacyclin) infusion in acute myocardial infarction. Br Heart J 1986; 56: 428-32.
    CrossrefPubMedGoogle Scholar
  • 32 Kuehl F A, Dougherty H W, Ham E A. Interactions between prostaglandins and leukotrienes. Biochem Pharmacol 1984; 33: 1-5.
    PubMedGoogle Scholar
  • 33 Lewis P J, Dollery C T. Clinical pharmacology and potential of prostacyclin. Br Med Bull 1983; 39: 281-4.
    CrossrefPubMedGoogle Scholar
  • 34 Marcus A J, Weksler B B, Jaffe E A, Broekman E J. Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest 1980; 66: 979-86.
    CrossrefPubMedGoogle Scholar
  • 35 Menitove J E, Frenzke M, Aster R H. Use of prostacyclin to inhibit activation of platelets during preparation of platelet concentrates. Transfusion 1984; 24: 528-31.
    CrossrefPubMedGoogle Scholar
  • 36 Miller D K, Sadowski S, Soderman D D, Kuehl F A. Endothelial cell prostacyclin production induced by activated neutrophils. J Biol Chem 1985; 260: 1006-14.
    PubMedGoogle Scholar
  • 37 Moncada S. Prostacyclin/thromboxane-mediated mechanisms in platelet-vascular wall interactions. Adv Prostaglandin Thromboxane Leukotriene Res 1985; 15: 507-12.
    PubMedGoogle Scholar
  • 38 Moncada S, Vane J R. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 1979; 30: 293-333.
    PubMedGoogle Scholar
  • 39 Moncada S, Gryglewski R, Bunting S, Vane J R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-5.
    CrossrefPubMedGoogle Scholar
  • 40 Musial J, Wilczynska M, Sladek K, Cierniewski C S, Nizankowski R, Szczeklik A. Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease. Prostaglandins 1986; 31: 61-70.
    CrossrefPubMedGoogle Scholar
  • 41 Neri G GSerneri, Modesti P A, Fortini A, Abbate R, Lombardi A, Gensini G F. Reduction of prostacyclin platelet receptors in active spontaneous angina. Lancet 1984; II: 838-41.
    PubMedGoogle Scholar
  • 42 Nizankowski R, Krolikowski W, Bielatowicz J, Szczeklik A. Prostacyclin for ischemic ulcers in peripheral arterial disease. A random assignment, placebo controlled study. Thromb Res 1985; 37: 21-8.
    CrossrefPubMedGoogle Scholar
  • 43 Oates J A, FitzGerald G A. Endogenous biosynthesis of prostacyclin and thromboxane A2 and the prevention of vascular occlusion in man. In: Prostacyclin Clinical Trials. Gryglewski R J, Szczeklik A, McGiff J C. (eds). New York: Raven Press; 1985: 115-23.
    Google Scholar
  • 44 Orchard M A, Blair I A, Dollery C T, Lewis P J. Blood can synthesize prostacyclin. Lancet 1983; II: 565.
    PubMedGoogle Scholar
  • 45 Payton C D, Belch J J F, Boulton J MJones. Successful treatment of thrombotic thrombocytopenic purpura by epoprostenol infusion. Lancet 1985; I: 927-8.
    PubMedGoogle Scholar
  • 46 Pedersen A K, Watson M L, FitzGerald G A. Inhibition of thromboxane biosynthesis in serum: limitations of the measurement of immunoreactive 6-keto-PGF1α . Thromb Res 1983; 33: 99-103.
    PubMedGoogle Scholar
  • 47 Prentice C R M, Belch J J F. Prostacyclin in Raynaud’s syndrome. In: Prostacyclin Clinical Trials. Gryglewski R J, Szczeklik A, McGiff J C. (eds). New York: Raven Press; 1985: 7-13.
    Google Scholar
  • 48 Prentice C R M, Belch J J F, McKay A, McArdle B, Leiberman P, Pollock J G, Lowe G D O, Forbes C D. Prostacyclin in severe arterial disease. In: Prostacyclin Clinical Trials. Gryglewski R J, Szczeklik A, McGiff J C. (eds). New York: Raven Press; 1985: 1-5.
    Google Scholar
  • 49 Price R M, Gersten D M, Ramwell P W. Macromolecules mediate prostacyclin release from human umbilical artery. Biochim Biophys Acta 1985; 836: 246-54.
    CrossrefPubMedGoogle Scholar
  • 50 Reinders J H, Brinkman H J M, von Mourik J A, de Groot P G. Cigarette smoke impairs endothelial cell prostacyclin production. Arteriosclerosis 1986; 06: 15-23.
    CrossrefPubMedGoogle Scholar
  • 51 Rossi V, Breviario F, Ghezzi P, Dejana E, Mantovani A. Prostacyclin synthesis induced in vascular cells by interleukin-1. Science 1985; 229: 174-6.
    CrossrefPubMedGoogle Scholar
  • 52 Rylance P B, Gordge M P, Ireland H, Lane D A, Weston M J. Hemodialysis with prostacyclin (epoprostenol) alone. ProcEur Dial Transplant Assoc Eur Ren Assoc 1985; 21: 281-6.
    PubMedGoogle Scholar
  • 53 Schafer A I, Crawford D D, Gimbrone M A. Unidirectional transfer of prostaglandin endoperoxides between platelets and endothelial cells. J Clin Invest 1984; 73: 1105-12.
    CrossrefPubMedGoogle Scholar
  • 54 Schrör K. Prostaglandins, other eicosanoids and endothelial cells. Basic Res Cardiol 1985; 80: 502-14.
    CrossrefPubMedGoogle Scholar
  • 55 Silberbauer K, Scherntaner G, Sinzinger H, Piza-Katzer H, Winter M. Decreased vascular prostacyclin in juvenile-onset diabetes. N Eng J Med 1979; 300: 366-7.
    PubMedGoogle Scholar
  • 56 Sinha A K, Dutta-Roy A K, Chin H C, Stewart G J, Colman R W. Coagulant factor Xa inhibits prostacyclin formation in human endothelial cells. Role of factor V. Arteriosclerosis 1985; 05: 244-9.
    CrossrefPubMedGoogle Scholar
  • 57 Sinzinger H, Feigl W, Silberbauer K. Prostacyclin generation in atherosclerotic arteries. Lancet 1979; II: 469.
    PubMedGoogle Scholar
  • 58 Sinzinger H, Silberbauer K, Horsch A K, Gall A. Decreased sensitivity of human platelets to PGI2 during long-term intraarterial prostacyclin infusion in patients with vascular disease a rebound phenomenon?. Prostaglandins 1981; 21: 49-51.
    CrossrefPubMedGoogle Scholar
  • 59 Sinzinger H, O’Grady J, Cromwell M, Hofer R. Epoprostenol (prostacyclin) decreases platelet deposition on vascular prosthetic graft. Lancet 1983; I: 1275-6.
    PubMedGoogle Scholar
  • 60 Sinzinger H, Leithner C, Silberbauer K. Rebound platelet activations during continuous epoprostenol infusion. Lancet 1984; II: 759.
    PubMedGoogle Scholar
  • 61 Sinzinger H, O’Grady J, Fitscha P, Kaliman J. Effect of epoprostenol on platelet deposition on synthetic artery grafts. Lancet 1984; II: 1212.
    PubMedGoogle Scholar
  • 62 Sinzinger H, Matejka M, Steurer G, Kaliman J, Ettl K. The interaction between the platelet derived growth factor (PDGF) and prostaglandin (PG) I2 is important for atherogenesis. 6th International Conference on Prostaglandins and Related Compounds. Abstract Book; 1986: 14.
    Google Scholar
  • 63 Smith W. Prostaglandin biosynthesis and its compartmentation in vascular smooth muscle and endothelial cells. Ann Rev Physiol 1986; 48: 251-62.
    CrossrefPubMedGoogle Scholar
  • 64 Szczeklik A, Kopec M, Sladek K, Musial J, Chmielewska J, Teisseyre E, Dudek-Wojciechowska G, Palester-Chlebowczyk M. Prostacyclin and the fibrinolytic system in ischemic vascular disease. Thromb Res 1983; 29: 655-60.
    CrossrefPubMedGoogle Scholar
  • 65 Vane J R. Clinical potential of prostacyclin. Adv Prostaglandin Thromboxane Leukotriene Res 1983; 11: 449-56.
    PubMedGoogle Scholar
  • 66 Von Euler U S. Über die spezifische blutdrucksenkende Substanz des menschlichen Prostataund Samenblasensekretes. Klin Wochenschr 1935; 33: 1182-3.
    PubMedGoogle Scholar
  • 67 Wautier J L, Pintigny D, Maclouf J, Wautier M P, Corvazier E, Caen J. Release of prostacyclin after erythrocyte adhesion to cultured vascular endothelium. J Lab Clin Med 1986; 107: 210-5.
    PubMedGoogle Scholar
  • 68 Weksler B B. Prostaglandins and vascular function. Circulation 1984; 70 (Suppl III): 63-71.
    CrossrefPubMedGoogle Scholar
  • 69 Weksler B B, Ley C W, Jaffe E A. Stimulation of endothelial cell prostacyclin production by thrombin, trypsin and the ionophore A 23187. J Clin Invest 1978; 62: 923-30.
    CrossrefPubMedGoogle Scholar
  • 70 Weston M J. Prostacyclin and extracorporeal circulation. Br Med Bull 1983; 39: 285-8.
    CrossrefPubMedGoogle Scholar
  • 71 Zwaal R F, Comfurius P, Hemker H C, Bevers E M. The inhibition of platelet prothrombinase activity by prostacyclin. Haemostasis 1984; 14: 320-4.
    PubMedGoogle Scholar